Cargando…

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT

BACKGROUND: Patients with heart failure (HF) are at high risk for atherosclerotic cardiovascular disease. Studies of atherothrombotic treatments in this population have been disappointing to date. Icosapent ethyl reduced the risk of atherosclerotic cardiovascular disease among a broad array of stati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Selvaraj, Senthil, Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Juliano, Rebecca A., Jiao, Lixia, Tardif, Jean‐Claude, Ballantyne, Christie M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075460/ https://www.ncbi.nlm.nih.gov/pubmed/35377160 http://dx.doi.org/10.1161/JAHA.121.024999

Ejemplares similares

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
por: Peterson, Benjamin E., et al.
Publicado: (2020)

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
por: Majithia, Arjun, et al.
Publicado: (2021)

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn
por: Miller, Michael, et al.
Publicado: (2023)

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
por: Peterson, Benjamin E., et al.
Publicado: (2022)

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021)

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022)

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
por: Kosmopoulos, Andrew, et al.
Publicado: (2021)

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results
por: Olshansky, Brian, et al.
Publicado: (2020)

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Wang, Xiaowen, et al.
Publicado: (2020)

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
por: Brinton, Eliot A, et al.
Publicado: (2013)

REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
por: Bhatt, Deepak L., et al.
Publicado: (2020)

Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside
por: Bhatt, Deepak L
Publicado: (2020)

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
por: Ballantyne, Christie M., et al.
Publicado: (2019)

Beyond cardiovascular medicine: potential future uses of icosapent ethyl
por: Bhatt, Deepak L, et al.
Publicado: (2020)

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl
por: Derington, Catherine G., et al.
Publicado: (2022)

Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
por: Bays, Harold E., et al.
Publicado: (2013)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Huston, Jessica, et al.
Publicado: (2023)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021)

Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review
por: Thakur, Mala, et al.
Publicado: (2020)

Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review
por: Sutariya, Bansi, et al.
Publicado: (2022)

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
por: Lachaine, Jean, et al.
Publicado: (2023)

Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)

Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020)

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin
por: Braeckman, Rene A., et al.
Publicado: (2014)

Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies
por: Hilleman, Daniel E., et al.
Publicado: (2014)

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
por: Parhofer, Klaus G, et al.
Publicado: (2020)

Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
por: Boden, William E, et al.
Publicado: (2020)

Icosapent Ethyl – A Successful Treatment for Symptomatic COVID-19 Infection
por: Berger, Amnon A, et al.
Publicado: (2020)

The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
por: Khan, Muhammad Shoaib, et al.
Publicado: (2021)

Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults
por: Braeckman, Rene A., et al.
Publicado: (2014)

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects
por: Braeckman, Rene A, et al.
Publicado: (2015)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFR(CT)
por: Rabbat, Mark G, et al.
Publicado: (2023)

Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes
por: Sabouret, Pierre François, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0i1nbvp7158hlvrtij4l8of8tb